Clinical trials: Non-Hodgkin Lymphoma, B-cell
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant in treating patients with leukemia or…
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma
- Trial name
- NCT02424968
- Testing
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Robert Lowsky
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma
- Trial name
- NCT00082888
- Testing
- Laboratory Biomarker Analysis, Tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
This phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement.
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
- Trial name
- NCT02446457
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT03483103
- Testing
- lisocabtagene maraleucel
- Where
- 59 sites in United States
- Volunteers
- 74 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment.
- Trial name
- NCT02997761
- Testing
- Blinatumomab, Ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of California, Davis
Marginal Zone B-cell Lymphoma
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
- Trial name
- NCT02433795
- Testing
- bendamustine plus rituximab
- Where
- 11 sites in South Korea
- Volunteers
- 27 people
- Sponsor
- Seoul National University Hospital
HIV-Associated Malignant Neoplasm, HIV Infections
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in…
- Conditions
- HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma
- Trial name
- NCT05510908
- Testing
- Non-Interventional, Non-Interventional Follow-up
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 460 people
- Sponsor
- AIDS Malignancy Consortium
Leukemia, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
RATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00133991
- Testing
- Filgrastim, Rituximab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia, Lymphoma
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional…
- Conditions
- Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes
- Trial name
- NCT00949117
- Testing
- Ensure, PediaSure, cyproheptadine hydrochloride
- Volunteers
- 9 people
- Sponsor
- University of South Florida
Leukemia
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Primary Objectives: 1. Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of oxaliplatin in combination with fludarabine, Ara-C and rituximab in patients with Richter's transformation, prolymphocytic…
- Trial name
- NCT00452374
- Testing
- Cytarabine, Fludarabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
The purpose of this study is to assess overall response rate [ORR, including complete response (CR) and partial response (PR)], of daratumumab in participants with non-Hodgkin's lymphoma [a cancer of the lymph nodes (or…
- Conditions
- Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- NCT02413489
- Testing
- Daratumumab
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or by presence of biomarkers associated with the…
- Trial name
- R-CHOP (NCT00450385)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- University of Miami
B-Cell Acute Lymphoblastic Leukemia, Adult
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL (B-ALL).
- Trial name
- NCT03160079
- Testing
- blinatumomab, pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego